A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of JNJ-67953964 in Subjects With Major Depressive Disorder
Latest Information Update: 07 Apr 2020
At a glance
- Drugs JNJ-67953964 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Janssen Research & Development; Janssen-Cilag
- 06 Mar 2020 Status changed from recruiting to active, no longer recruiting.
- 17 Oct 2019 Planned primary completion date changed from 11 Nov 2019 to 13 May 2020.
- 08 Mar 2019 Planned number of patients changed from 142 to 172.